Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

thyroid cancer

Eli Lilly HQ

Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

Armo is developing IL-10 drugs for potential combination with established immunotherapies

How published research underpinned a cancer therapy awareness campaign

Our client markets a product for Oral Mucositis (OM) - a side effect of cancer treatment - and wanted to better understand the disease and treatment challenges faced by both...

Research Partnership

How a hybrid approach delivered fast insights to feed into an oncology product’s adoption strategy

Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests...

Research Partnership

Oncology experience & expertise

Did you know 25% of our business is in Oncology?

Research Partnership

- PMLiVE

FDA panel undermines Lilly and Incyte’s baricitinib hopes

Mixed review doesn’t bode well in competitive market

- PMLiVE

Shire offloads oncology unit to Servier for $2.4bn

The French drugmaker will also acquire Oncaspar and Onivyde as part of the deal

- PMLiVE

Beyond caring: learning from the unsung advocates in cancer care

Macmillan Cancer Support estimates that there are currently around 1.5 million carers caring for someone who has cancer in the UK. Broadly, carers in and outside cancer contribute around £132...

- PMLiVE

AbbVie’s upadacitinib aces phase III trial

Arthritis drug outperformed both placebo and Humira in the study

How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market

Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led...

Research Partnership

Research conducted by Research Partnership published in leading medical journal

Findings from a study conducted by Research Partnership have recently been published in the ‘Supportive Care in Cancer’ journal

Research Partnership

Eli Lilly HQ

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

Studies show the drug improves PFS when used with an aromatase inhibitor

EISAI

NICE reverses its rejection of Eisai’s Lenvima

The cost-effectiveness watchdog has now backed the thyroid cancer treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links